×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VERU – veru inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VERU
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
08:19 am
veru
Veru Inc. (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Veru Inc. (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
11/26
08:38 am
veru
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders [Yahoo! Finance]
Medium
Report
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders [Yahoo! Finance]
11/26
08:30 am
veru
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
Medium
Report
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
11/6
08:07 am
veru
Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.
Low
Report
Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.
11/5
08:30 am
veru
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Medium
Report
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
10/21
08:30 am
veru
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
Medium
Report
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
10/16
08:30 am
veru
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Low
Report
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Date
Time
Symbol
Headline
Impact
12/16
03:49 pm
veru
Form 10-K VERU INC. For: Sep 30
Medium
Report
Form 10-K VERU INC. For: Sep 30
11/12
09:37 am
veru
Form SC 13G/A VERU INC. Filed by: Adage Capital Management, L.P.
Medium
Report
Form SC 13G/A VERU INC. Filed by: Adage Capital Management, L.P.
11/8
02:22 pm
veru
Form SC 13G VERU INC. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G VERU INC. Filed by: BlackRock, Inc.
11/4
04:19 pm
veru
Form SC 13G/A VERU INC. Filed by: MILLENNIUM MANAGEMENT LLC
Low
Report
Form SC 13G/A VERU INC. Filed by: MILLENNIUM MANAGEMENT LLC
10/24
02:03 pm
veru
Form SC 13G VERU INC. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G VERU INC. Filed by: BlackRock, Inc.
10/2
05:05 pm
veru
Form 4 VERU INC. For: Oct 01 Filed by: Hyun Grace
Low
Report
Form 4 VERU INC. For: Oct 01 Filed by: Hyun Grace
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/13
Is Paratek Pharmaceuticals Inc (PRTK) Going to Burn These Hedge Funds? [Yahoo! Finance News]
25.0%
12/13 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. 12.1%
6/4 Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA 8.8%
1/21 Veru Inc (NASDAQ: VERU) had its "reduce" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, up previously from $4.50. 8.8%
2/19 Form 4 VERU INC. For: Feb 19 Filed by: Socorro Jesus 7.8%
9/28 Veru Inc (NASDAQ: VERU) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. 7.5%
8/28 Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York 6.6%
3/4 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 5.1%
5/3 Form 4 VERU INC. For: May 01 Filed by: STEINER MITCHELL SHUSTER 4.1%
11/2 Veru Inc (NASDAQ: VERU) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 4.1%
12/13 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. 12.1%
6/4 Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA 8.8%
1/21 Veru Inc (NASDAQ: VERU) had its "reduce" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, up previously from $4.50. 8.8%
2/19 Form 4 VERU INC. For: Feb 19 Filed by: Socorro Jesus 7.8%
9/28 Veru Inc (NASDAQ: VERU) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. 7.5%
8/28 Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York 6.6%
3/4 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 5.1%
5/3 Form 4 VERU INC. For: May 01 Filed by: STEINER MITCHELL SHUSTER 4.1%
11/2 Veru Inc (NASDAQ: VERU) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 4.1%
TOP News Decliners
8/27
Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month
-9.5%
8/8 Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter -9.4%
12/12 Form 8-K VERU INC. For: Dec 12 -7.7%
8/9 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. -7.5%
5/15 Q2/2019 3/31/2019 EPS -0.060 ZacksConsensus -0.050 ActVsEst (0.010) - Miss -7.1%
6/6 Veru Inc (NASDAQ: VERU) was given a new $5.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -6.3%
8/1 Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th -6.3%
1/28 Form DEF 14A VERU INC. For: Mar 24 -5.4%
1/25 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.4%
1/13 Veru's experimental drug reduces hot flashes in men in mid-stage study [Reuters (UK)] -3.9%
8/8 Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter -9.4%
12/12 Form 8-K VERU INC. For: Dec 12 -7.7%
8/9 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. -7.5%
5/15 Q2/2019 3/31/2019 EPS -0.060 ZacksConsensus -0.050 ActVsEst (0.010) - Miss -7.1%
6/6 Veru Inc (NASDAQ: VERU) was given a new $5.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -6.3%
8/1 Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th -6.3%
1/28 Form DEF 14A VERU INC. For: Mar 24 -5.4%
1/25 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.4%
1/13 Veru's experimental drug reduces hot flashes in men in mid-stage study [Reuters (UK)] -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: